Wright Medical Group NV (NASDAQ:WMGI) CAO Julie Andrews sold 1,447 shares of Wright Medical Group stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $30.65, for a total transaction of $44,350.55. The sale was disclosed in a filing with the SEC, which is available at the SEC website.
NASDAQ WMGI opened at $29.82 on Friday. The company has a quick ratio of 0.70, a current ratio of 0.91 and a debt-to-equity ratio of 0.79. The stock has a market cap of $3.66 billion, a P/E ratio of 724.75, a price-to-earnings-growth ratio of 8.78 and a beta of 0.82. The firm’s 50-day simple moving average is $31.13. Wright Medical Group NV has a one year low of $24.10 and a one year high of $32.86.
Wright Medical Group (NASDAQ:WMGI) last posted its earnings results on Tuesday, May 7th. The medical device company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. The business had revenue of $230.13 million for the quarter, compared to the consensus estimate of $226.10 million. Wright Medical Group had a negative net margin of 20.81% and a positive return on equity of 0.84%. The company’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.01) EPS. As a group, equities research analysts expect that Wright Medical Group NV will post 0.22 earnings per share for the current year.
A number of brokerages recently weighed in on WMGI. BidaskClub lowered shares of Wright Medical Group from a “buy” rating to a “hold” rating in a report on Thursday, May 23rd. Oppenheimer set a $34.00 price objective on shares of Wright Medical Group and gave the company a “hold” rating in a report on Wednesday, May 8th. Wells Fargo & Co reiterated a “buy” rating on shares of Wright Medical Group in a report on Monday, March 11th. BMO Capital Markets lifted their price objective on shares of Wright Medical Group from $33.00 to $36.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $38.00 price objective on shares of Wright Medical Group in a report on Wednesday, April 10th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $35.17.
Wright Medical Group Company Profile
Wright Medical Group N.V., a medical device company, designs, manufactures, markets, and sells upper and lower extremities, and biologics products in the United States, Europe, the Middle East, Africa, Canada, Asia, Australia, and Latin America. The company offers joint implants and bone fixation devices for the shoulder, elbow, wrist, hand, foot, and ankle; and biologics products that are used for supporting the treatment of damaged or diseased bones, tendons, and soft tissues, as well as to stimulate bone growth.
Further Reading: Golden Cross
Receive News & Ratings for Wright Medical Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wright Medical Group and related companies with MarketBeat.com's FREE daily email newsletter.